Bempedoic Acid: First Approval

[1]  M. Sheikh-Ali,et al.  A Review of the Efficacy and Tolerability of Bempedoic Acid in the Treatment of Hypercholesterolemia , 2020, American Journal of Cardiovascular Drugs.

[2]  Lawrence A Leiter,et al.  Effect of Bempedoic Acid vs Placebo Added to Maximally Tolerated Statins on Low-Density Lipoprotein Cholesterol in Patients at High Risk for Cardiovascular Disease: The CLEAR Wisdom Randomized Clinical Trial. , 2019, JAMA.

[3]  Lawrence A Leiter,et al.  Efficacy and Safety of Bempedoic Acid + Ezetimibe Fixed-Dose Combination in Patients at High CVD Risk and with Elevated LDL-C Receiving Maximally Tolerated Statin Therapy , 2019, Atherosclerosis.

[4]  Lawrence A Leiter,et al.  Bempedoic acid plus ezetimibe fixed-dose combination in patients with hypercholesterolemia and high CVD risk treated with maximally tolerated statin therapy , 2019, European journal of preventive cardiology.

[5]  J. Mckenney,et al.  Lipid Lowering With Bempedoic Acid Added to Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor Therapy: A Randomized Controlled Trial , 2019, Journal of Clinical Lipidology.

[6]  S. Nicholls,et al.  Efficacy and Safety of Triplet Therapy With Bempedoic Acid, Ezetimibe, and Atorvastatin in Patients with Hypercholesterolemia , 2019, Journal of Clinical Lipidology.

[7]  D. Gaudet,et al.  Efficacy and Safety of Bempedoic Acid in Patients With Hypercholesterolemia and Statin Intolerance , 2019, Journal of the American Heart Association.

[8]  C. Ballantyne,et al.  Safety and Efficacy of Bempedoic Acid to Reduce LDL Cholesterol , 2019, The New England journal of medicine.

[9]  Lawrence A Leiter,et al.  Efficacy and safety of bempedoic acid added to ezetimibe in statin-intolerant patients with hypercholesterolemia: A randomized, placebo-controlled study. , 2018, Atherosclerosis.

[10]  Stephen L. Pinkosky,et al.  Liver-specific ATP-citrate lyase inhibition by bempedoic acid decreases LDL-C and attenuates atherosclerosis , 2016, Nature Communications.

[11]  J. Mckenney,et al.  Treatment with ETC-1002 alone and in combination with ezetimibe lowers LDL cholesterol in hypercholesterolemic patients with or without statin intolerance. , 2016, Journal of clinical lipidology.

[12]  P. Thompson,et al.  Use of ETC-1002 to treat hypercholesterolemia in patients with statin intolerance. , 2015, Journal of clinical lipidology.

[13]  M. Milad,et al.  Efficacy and Safety of ETC-1002, a Novel Investigational Low-Density Lipoprotein-Cholesterol–Lowering Therapy for the Treatment of Patients With Hypercholesterolemia and Type 2 Diabetes Mellitus , 2014, Arteriosclerosis, thrombosis, and vascular biology.

[14]  C. Ballantyne,et al.  Efficacy and safety of a novel dual modulator of adenosine triphosphate-citrate lyase and adenosine monophosphate-activated protein kinase in patients with hypercholesterolemia: results of a multicenter, randomized, double-blind, placebo-controlled, parallel-group trial. , 2013, Journal of the American College of Cardiology.

[15]  Khosrow Adeli,et al.  AMP-activated protein kinase and ATP-citrate lyase are two distinct molecular targets for ETC-1002, a novel small molecule regulator of lipid and carbohydrate metabolism[S] , 2013, Journal of Lipid Research.